FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC

The FDA approved the use of durvalumab combined with enfortumab vedotin as a perioperative treatment followed by adjuvant durvalumab for adult muscle invasive bladder cancer (MIBC) patients who are ineligible for or refuse cisplatin chemotherapy. This approval is based on the phase 3 VOLGA trial that demonstrated significant improvements in event-free and overall survival compared to surgery alone.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it.